Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men.

Lee GA, Schwarz JM, Patzek S, Kim S, Dyachenko A, Wen M, Mulligan K, Schambelan M, Grunfeld C.

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):246-8. doi: 10.1097/QAI.0b013e3181b03214.

2.
3.

Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.

Lee GA, Rao M, Mulligan K, Lo JC, Aweeka F, Schwarz JM, Schambelan M, Grunfeld C.

AIDS. 2007 Oct 18;21(16):2183-90.

5.

Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.

Taylor SA, Lee GA, Pao VY, Anthonypillai J, Aweeka FT, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C.

J Acquir Immune Defic Syndr. 2010 Nov;55(3):361-4. doi: 10.1097/QAI.0b013e3181e6a7d9.

6.

Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.

Schütt M, Zhou J, Meier M, Klein HH.

J Endocrinol. 2004 Dec;183(3):445-54.

PMID:
15590971
8.

Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.

Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C.

AIDS. 2002 Mar 29;16(5):F1-8.

9.

Alteration in pancreatic islet function in human immunodeficiency virus.

Haugaard SB.

Endocrinol Metab Clin North Am. 2014 Sep;43(3):697-708. doi: 10.1016/j.ecl.2014.06.004. Review.

PMID:
25169562
10.

Indinavir increases glucose production in healthy HIV-negative men.

Schwarz JM, Lee GA, Park S, Noor MA, Lee J, Wen M, Lo JC, Mulligan K, Schambelan M, Grunfeld C.

AIDS. 2004 Sep 3;18(13):1852-4.

PMID:
15316349
11.

Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects.

Dubé MP, Gorski JC, Shen C.

Cardiovasc Toxicol. 2008 Mar;8(1):15-22. doi: 10.1007/s12012-007-9010-y. Epub 2008 Jan 3.

12.

Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy.

Young EM, Considine RV, Sattler FR, Deeg MA, Buchanan TA, Degawa-Yamauchi M, Shankar S, Edmondson-Melançon H, Hernandez J, Dubé MP.

Cardiovasc Toxicol. 2004;4(2):179-86.

PMID:
15371633
13.

Metabolic effects of indinavir in healthy HIV-seronegative men.

Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C.

AIDS. 2001 May 4;15(7):F11-8.

14.

Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.

Gan SK, Samaras K, Thompson CH, Kraegen EW, Carr A, Cooper DA, Chisholm DJ.

Diabetes. 2002 Nov;51(11):3163-9.

15.

In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.

Shibata N, Gao W, Okamoto H, Kishida T, Yoshikawa Y, Takada K.

J Pharm Pharmacol. 2002 Feb;54(2):221-9.

PMID:
11848286
16.

Drug interactions. Amprenavir with low-dose ritonavir.

[No authors listed]

TreatmentUpdate. 2006 Jun-Jul;18(3):9-10. No abstract available.

PMID:
17211921
17.

The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.

Lee GA, Rao MN, Grunfeld C.

Curr HIV/AIDS Rep. 2005 Feb;2(1):39-50. Review.

PMID:
16091248
18.

The safety and antiviral effect of protease inhibitors in children.

Temple ME, Koranyi KI, Nahata MC.

Pharmacotherapy. 2001 Mar;21(3):287-94.

PMID:
11253853
20.

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA.

AIDS. 1998 May 7;12(7):F51-8.

PMID:
9619798

Supplemental Content

Support Center